Different origins of lysophospholipid mediators between coronary and peripheral arteries in acute coronary syndrome

Journal of Lipid Research

Volumn 58, Issue 2, 2017, Pages 433-442

  Kurano, Makoto ^a,b   Kano, Kuniyuki ^b,c   Dohi, Tomotaka ^d   Matsumoto, Hirotaka ^c   Igarashi, Koji ^e   Nishikawa, Masako ^a,b   Ohkawa, Ryunosuke ^f   Ikeda, Hitoshi ^a,b,f   Miyauchi, Katsumi ^d   Daida, Hiroyuki ^d   Aoki, Junken ^a,c   Yatomi, Yutaka ^a,b,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOSOH CORPORATION   (Japan)

^f UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Acute coronary disease; Lysophosphatidic acids; Lysophosphatidylcholine; Lysophosphatidylethanolamine; Lysophosphatidylserine

Indexed keywords

AUTOTAXIN; AUTOTAXIN ALPHA; AUTOTAXIN BETA; AUTOTAXIN DELTA; AUTOTAXIN EPSILON; AUTOTAXIN GAMMA; CHOLINE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLSERINE; PHOSPHOLIPASE A1; UNCLASSIFIED DRUG; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; LYSOPHOSPHATIDYLGLYCEROL; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID; PHOSPHODIESTERASE;

ACUTE CORONARY SYNDROME; ALTERNATIVE RNA SPLICING; ARTICLE; BLOOD SAMPLING; CAUSAL ATTRIBUTION; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ATHEROSCLEROSIS; BLOOD; CORONARY BLOOD VESSEL; FEMALE; HEART; MALE; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CORONARY VESSELS; FEMALE; HEART; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MASS SPECTROMETRY; PHOSPHOLIPASES A1; PHOSPHORIC DIESTER HYDROLASES;

EID: 85011317430     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P071803     Document Type: Article

References (49)

1. Teo, S. T., Y. C. Yung, D. R. Herr, and J. Chun. 2009. Lysophosphatidic acid in vascular development and disease. IUBMB Life. 61: 791-799.
2. Rizza, C., N. Leitinger, J. Yue, D. J. Fischer, D. A. Wang, P. T. Shih, H. Lee, G. Tigyi, and J. A. Berliner. 1999. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab. Invest. 79: 1227-1235.
3. Lin, C. I., C. N. Chen, P. W. Lin, K. J. Chang, F. J. Hsieh, and H. Lee. 2007. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3. Biochem. Biophys. Res. Commun. 363: 1001-1008.
4. Tigyi, G. 2001. Physiological responses to lysophosphatidic acid and related glycero-phospholipids. Prostaglandins Other Lipid Mediat. 64: 47-62.
5. Siess, W. 2002. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim. Biophys. Acta. 1582: 204-215.
6. Siess, W., and G. Tigyi. 2004. Thrombogenic and atherogenic activities of lysophosphatidic acid. J. Cell. Biochem. 92: 1086-1094.
7. Pamuklar, Z., J. S. Lee, H. Y. Cheng, M. Panchatcharam, S. Steinhubl, A. J. Morris, R. Charnigo, and S. S. Smyth. 2008. Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler. Thromb. Vasc. Biol. 28: 555-561.
8. Kishimoto, T., T. Matsuoka, S. Imamura, and K. Mizuno. 2003. A novel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. Clin. Chim. Acta. 333: 59-67.
9. Dohi, T., K. Miyauchi, R. Ohkawa, K. Nakamura, T. Kishimoto, T. Miyazaki, A. Nishino, N. Nakajima, K. Yaginuma, H. Tamura, et al. 2012. Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin. Chim. Acta. 413: 207-212.
10. Dohi, T., K. Miyauchi, R. Ohkawa, K. Nakamura, M. Kurano, T. Kishimoto, N. Yanagisawa, M. Ogita, T. Miyazaki, A. Nishino, et al. 2013. Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome. Atherosclerosis. 229: 192-197.
11. Kurano, M., A. Suzuki, A. Inoue, Y. Tokuhara, K. Kano, H. Matsumoto, K. Igarashi, R. Ohkawa, K. Nakamura, T. Dohi, et al. 2015. Possible involvement of minor lysophospholipids in the increase in plasma lysophosphatidic Acid in acute coronary syndrome. Arterioscler. Thromb. Vasc. Biol. 35: 463-470.
12. Kurano, M., T. Dohi, T. Nojiri, T. Kobayashi, Y. Hirowatari, A. Inoue, K. Kano, H. Matsumoto, K. Igarashi, M. Nishikawa, et al. 2015. Blood levels of serotonin are specifically correlated with plasma lysophosphatidylserine among the glycero-lysophospholipids. BBA Clin. 4: 92-98.
13. Nishikawa, M., M. Kurano, H. Ikeda, J. Aoki, and Y. Yatomi. 2015. Lysophosphatidylserine has bilateral effects on macrophages in the pathogenesis of atherosclerosis. J. Atheroscler. Thromb. 22: 518-526.
14. Bellini, F., and A. Bruni. 1993. Role of a serum phospholipase A1 in the phosphatidylserine-induced T cell inhibition. FEBS Lett. 316: 1-4.
15. Barnes, M. J., C. M. Li, Y. Xu, J. An, Y. Huang, and J. G. Cyster. 2015. The lysophosphatidylserine receptor GPR174 constrains regulatory T cell development and function. J. Exp. Med. 212: 1011-1020.
16. Siess, W., K. J. Zangl, M. Essler, M. Bauer, R. Brandl, C. Corrinth, R. Bittman, G. Tigyi, and M. Aepfelbacher. 1999. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 96: 6931-6936.
17. Tan, X., J. Shi, Y. Fu, C. Gao, X. Yang, J. Li, W. Wang, J. Hou, H. Li, and J. Zhou. 2013. Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb. Haemost. 109: 1025-1032.
18. Nagata, S., J. Suzuki, K. Segawa, and T. Fujii. 2016. Exposure of phosphatidylserine on the cell surface. Cell Death Differ. 23: 952-961.
19. Blanco-Colio, L. M., J. L. Martin-Ventura, E. de Teresa, C. Farsang, A. Gaw, G. Gensini, L. A. Leiter, A. Langer, P. Martineau, G. Hernandez, et al. 2007. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler. Thromb. Vasc. Biol. 27: 168-174.
20. Niessner, A., P. J. Hohensinner, K. Rychli, S. Neuhold, G. Zorn, B. Richter, M. Hulsmann, R. Berger, D. Mortl, K. Huber, et al. 2009. Prognostic value of apoptosis markers in advanced heart failure patients. Eur. Heart J. 30: 789-796.
21. Okudaira, M., A. Inoue, A. Shuto, K. Nakanaga, K. Kano, K. Makide, D. Saigusa, Y. Tomioka, and J. Aoki. 2014. Separation and quantification of 2-acyl-1-lysophospholipids and 1-acyl-2-lysophospholipids in biological samples by LC-MS/MS. J. Lipid Res. 55: 2178-2192.
22. Nakamura, K., K. Igarashi, K. Ide, R. Ohkawa, S. Okubo, H. Yokota, A. Masuda, N. Oshima, T. Takeuchi, M. Nangaku, et al. 2008. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin. Chim. Acta. 388: 51-58.
23. Nakamura, K., K. Igarashi, R. Ohkawa, N. Saiki, M. Nagasaki, K. Uno, N. Hayashi, T. Sawada, K. Syukuya, H. Yokota, et al. 2010. A novel enzyme immunoassay for the determination of phosphatidylserine- specific phospholipase A(1) in human serum samples. Clin. Chim. Acta. 411: 1090-1094.
24. Tokuhara, Y., M. Kurano, S. Shimamoto, K. Igarashi, T. Nojiri, T. Kobayashi, A. Masuda, H. Ikeda, T. Nagamatsu, T. Fujii, et al. 2015. A new enzyme immunoassay for the quantitative determination of classical autotaxins (ATXα, ATXβ, and ATXγ) and novel autotaxins (ATXδ and ATX). PLoS One. 10: e0130074.
25. Spector, A. A. 2003. Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation. 108: 641-643.
26. Smyth, S. S., H. Y. Cheng, S. Miriyala, M. Panchatcharam, and A. J. Morris. 2008. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim. Biophys. Acta. 1781: 563-570.
27. Makide, K., H. Kitamura, Y. Sato, M. Okutani, and J. Aoki. 2009. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat. 89: 135-139.
28. Makide, K., A. Uwamizu, Y. Shinjo, J. Ishiguro, M. Okutani, A. Inoue, and J. Aoki. 2014. Novel lysophosphoplipid receptors: their structure and function. J. Lipid Res. 55: 1986-1995.
29. Harayama, T., M. Eto, H. Shindou, Y. Kita, E. Otsubo, D. Hishikawa, S. Ishii, K. Sakimura, M. Mishina, and T. Shimizu. 2014. Lysophospholipid acyltransferases mediate phosphatidylcholine diversification to achieve the physical properties required in vivo. Cell Metab. 20: 295-305.
30. Samadi, N., R. Bekele, D. Capatos, G. Venkatraman, M. Sariahmetoglu, and D. N. Brindley. 2011. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie. 93: 61-70.
31. Hosogaya, S., Y. Yatomi, K. Nakamura, R. Ohkawa, S. Okubo, H. Yokota, M. Ohta, H. Yamazaki, T. Koike, and Y. Ozaki. 2008. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann. Clin. Biochem. 45: 364-368.
32. van Meeteren, L. A., P. Ruurs, C. Stortelers, P. Bouwman, M. A. van Rooijen, J. P. Pradere, T. R. Pettit, M. J. Wakelam, J. S. Saulnier- Blache, C. L. Mummery, et al. 2006. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26: 5015-5022.
33. Erbilgin, A., M. Civelek, C. E. Romanoski, C. Pan, R. Hagopian, J. A. Berliner, and A. J. Lusis. 2013. Identification of CAD candidate genes in GWAS loci and their expression in vascular cells. J. Lipid Res. 54: 1894-1905.
34. Panchatcharam, M., S. Miriyala, A. Salous, J. Wheeler, A. Dong, P. Mueller, M. Sunkara, D. Escalante-Alcalde, A. J. Morris, and S. S. Smyth. 2013. Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 33: 52-59.
35. Smyth, S. S., P. Mueller, F. Yang, J. A. Brandon, and A. J. Morris. 2014. Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 34: 479-486.
36. Glomset, J. A. 1968. The plasma lecithins:cholesterol acyltransferase reaction. J. Lipid Res. 9: 155-167.
37. Murugesan, G., and P. L. Fox. 1996. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J. Clin. Invest. 97: 2736-2744.
38. Sekas, G., G. M. Patton, E. C. Lincoln, and S. J. Robins. 1985. Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. J. Lab. Clin. Med. 105: 190-194.
39. Robinson, B. S., D. J. Baisted, and D. E. Vance. 1989. Comparison of albumin-mediated release of lysophosphatidylcholine and lysophosphatidylethanolamine from cultured rat hepatocytes. Biochem. J. 264: 125-131.
40. Yokoyama, K., F. Shimizu, and M. Setaka. 2000. Simultaneous separation of lysophospholipids from the total lipid fraction of crude biological samples using two-dimensional thin-layer chromatography. J. Lipid Res. 41: 142-147.
41. Ou, Z. J., L. Li, X. L. Liao, Y. M. Wang, X. X. Hu, Q. L. Zhang, Z. P. Wang, H. Yu, X. Zhang, P. Hu, et al. 2012. Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by altering plasma metabolites in hypercholesterolemia. Am. J. Physiol. Endocrinol. Metab. 303: E683-E694.
42. Kim, J., J. W. Lampe, T. Yin, K. Shinozaki, and L. B. Becker. 2015. Phospholipid alterations in the brain and heart in a rat model of asphyxia-induced cardiac arrest and cardiopulmonary bypass resuscitation. Mol. Cell. Biochem. 408: 273-281.
43. Aoki, J., A. Taira, Y. Takanezawa, Y. Kishi, K. Hama, T. Kishimoto, K. Mizuno, K. Saku, R. Taguchi, and H. Arai. 2002. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J. Biol. Chem. 277: 48737-48744.
44. Pamuklar, Z., L. Federico, S. Liu, M. Umezu-Goto, A. Dong, M. Panchatcharam, Z. Fulkerson, E. Berdyshev, V. Natarajan, X. Fang, et al. 2009. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J. Biol. Chem. 284: 7385-7394. [Erratum. 2009. J. Biol. Chem. 284: 21100.]
45. Sciorra, V. A., and A. J. Morris. 2002. Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim. Biophys. Acta. 1582: 45-51.
46. Ren, H., M. Panchatcharam, P. Mueller, D. Escalante-Alcalde, A. J. Morris, and S. S. Smyth. 2013. Lipid phosphate phosphatase (LPP3) and vascular development. Biochim. Biophys. Acta. 1831: 126-132.
47. Sonoda, H., J. Aoki, T. Hiramatsu, M. Ishida, K. Bandoh, Y. Nagai, R. Taguchi, K. Inoue, and H. Arai. 2002. A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J. Biol. Chem. 277: 34254-34263.
48. Aoki, J., Y. Nagai, H. Hosono, K. Inoue, and H. Arai. 2002. Structure and function of phosphatidylserine-specific phospholipase A1. Biochim. Biophys. Acta. 1582: 26-32.
49. Bandoh, K., J. Aoki, H. Hosono, S. Kobayashi, T. Kobayashi, K. Murakami-Murofushi, M. Tsujimoto, H. Arai, and K. Inoue. 1999. Molecular cloning and characterization of a novel human G-proteincoupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274: 27776-27785.